IM Cannabis director Einat Zakariya resigns from board
The Nasdaq-listed medical cannabis company said the departure was for personal reasons and unrelated to any disagreement over operations.
IM Cannabis Corp. (Nasdaq: IMCC) disclosed in a Form 6-K filed September 28, 2026 that Einat Zakariya resigned as a director of the company and as a member of all committees of the board of directors, effective September 27, 2026, for personal reasons.1
The company's filing said Zakariya's resignation was not related to any disagreement with the company on any matter relating to its operations, policies or practices.1 The board and management thanked Zakariya for her service and contributions and extended best wishes for her future endeavours.1
The filing also restated the company's background as an international company operating a medical cannabis platform serving patients in Israel and, through Adjupharm GmbH, Germany.1 It noted that as previously announced on August 17, 2026, the company entered into an agreement to sell I.M.C. Holdings Ltd.1 Once that deal closes, the company said it plans to keep its Israeli medical cannabis business while the buyer would end up indirectly controlling the German operations run through Adjupharm GmbH.
The filing described the company's Israeli operations as running through subsidiaries that handle cannabis imports and distribution to patients using data built up over time, and said the company also runs retail pharmacies and online platforms in Israel meant to manage product delivery and quality from the value chain.
The 6-K, IM Cannabis's sixth report of the month, was signed by Chief Executive Officer Oren Shuster on September 28, 2026, and is incorporated by reference into several of the company's registration statements on Form F-3, including File Nos. 333-296637, 333-293236, 333-289571 and 333-288346.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.